Early access
Sign in
Taking people in PortugalNo phase

Blood tests being studied to help detect ovarian cancer

Compares investigational blood tests in women with and without ovarian cancer.

Key facts

Who runs it
National and Kapodistrian University of Athens
Where
Lisbon, PortugalSee the siteAlso in 4 other countries, 6 sites
Trial code
Registry title
Innovative Ovarian Cancer Biomarker Assays
Status
Recruiting
People taking part
2,080 people, planned
Started
3 Aug 2026
Expected to end
Dec 2028
Type of study
Observational, 2 groups
Treatments tested
  • Investigational ovarian cancer biomarker assays
Record updated
1 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for women aged 35 or older with newly diagnosed epithelial ovarian cancer, and women of the same age with no cancer history as comparison. It tests blood-based ovarian cancer tests.

Age
35 years or older
Sex
Women, trans men and non-binary people with female reproductive organs
Disease stage
Cancer patients: epithelial ovarian cancer confirmed by biopsy before any surgery or treatment, with a suspicious mass near the ovary on imaging, and surgery or biopsy scheduled. Comparison group: no cancer history.
Earlier treatment
Patients must not have had surgery or treatment for the ovarian cancer before joining. Nobody can have had treatment for any cancer before.

Main reasons for not taking part

  • Earlier cancer or treatment for cancer
  • Either ovary removed before, for any reason
  • Pregnant or breastfeeding
  • Any condition the investigator thinks could stop the person from taking part or following the study

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • EOC patients
  • Women, trans men and non-binary people with female reproductive organs
  • Aged ≥35 years*
  • Pathologically diagnosed, by biopsy, with EOC prior to surgical intervention or treatment
  • Presenting with adnexal mass suspicious of OC on imaging and scheduled for surgical resection or biopsy (and subsequent confirmation of EOC)
  • Able to give informed consent; Healthy controls
  • Women, trans men and non-binary people with female reproductive organs
  • Aged ≥35 years
  • No cancer history
  • Able to give informed consent

Who cannot take part

  • Prior history and any treatment for malignancy
  • Prior removal of either ovary for any reason
  • Any condition or circumstance that, in the opinion of the investigator, could interfere with the participant's ability to participate or comply with study requirements
  • Pregnant or lactating

Where in Portugal

Also in 4 other countries, 6 sites

  • Instituto Portugues de Oncologia de Lisboa Francisco Gentil, E.P.E.Lisbon, PortugalContact: Fatima VAZTaking people

About the trial

What the trial wants to find out

Ovarian cancer is often diagnosed at a later stage because early symptoms can be mild or non-specific. Earlier detection of ovarian cancer could improve treatment options and outcomes.

Read full original descriptionShow less

Recent research has focused on the development of blood-based tests, sometimes referred to as liquid biopsy tests, which aim to look for changes in the blood that could be linked to cancer. These tests are still under investigation and are not part of routine clinical care.

The purpose of this study is to evaluate several blood-based ovarian cancer tests. This will be done by comparing test results from people who have ovarian cancer with results from people who do not have cancer.

The study will also collect information from standard blood tests and genetic analyses to better understand how these results relate to ovarian cancer.

This study is for research purposes only. The blood-based tests being evaluated are investigational and are not used to make medical decisions or diagnoses for women taking part in the study.

The 2 groups in the trial

  • Epithelial Ovarian Cancer

    Women with epithelial ovarian cancer prior to surgical intervention or treatment. Participants present with an adnexal mass suspicious of ovarian cancer and are subsequently classified based on histopathological diagnosis.

    Treatment: Investigational ovarian cancer biomarker assays

  • Healthy controls

    Healthy controls without a cancer diagnosis recruited for comparison with participants with epithelial ovarian cancer.

    Treatment: Investigational ovarian cancer biomarker assays

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Multi-site, Multi-country Evaluation of Innovative Ovarian Cancer Biomarker Assays. (DISARM Clinical Study B-CSB)
Plain-language title
Blood tests being studied to help detect ovarian cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
1 October 2026